Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
Pediatrics. 2007 Jun; 119(6):1076-82.Ped

Abstract

OBJECTIVES

We conducted this study to test the hypothesis that intradermal influenza vaccination at one fifth of a standard dose elicits comparable immunogenicity to full-dose intramuscular vaccination in children.

PATIENTS AND METHODS

We conducted a randomized, open-label study in 112 healthy children aged 3 to <18 years to compare the immunogenicity and safety of intradermal vaccination at one fifth of a dose with standard intramuscular vaccination. Analyses of hemagglutination inhibition antibody titers to each antigen in each group included geometric mean titers before and 21 days after vaccination, fold increase in geometric mean titers after vaccination, seroprotection rate, and seroconversion rate.

RESULTS

The mean age of the subjects was 10.11 +/- 4.04 years in the intradermal vaccination group and 10.57 +/- 3.91 years in the intramuscular group. Intradermal vaccination was safe. Induration and mild erythema at the injection site were reported at 25% and 57%, respectively, in the intradermal group. Fold increase of geometric mean titers against influenza A/Caledonia was robust in both groups (11.1-fold and 12.9-fold increase in the intramuscular and intradermal groups, respectively), whereas that for B/Shandong was more modest (4.3-4.4). Both approaches elicited very high geometric mean titers against influenza A/Panama: 1360.5 and 893.9 for the intramuscular and intradermal groups, respectively, but because the prevaccination antibody titers were high, the fold increase of geometric mean titers was only 4.5 and 2.6, respectively.

CONCLUSION

The immunogenicity of one fifth of a dose of influenza vaccine delivered by the intradermal route is comparable to the standard-dose intramuscular vaccination in children as young as 3 years of age.

Authors+Show Affiliations

Department of Pediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong, China. ssschiu@hkucc.hku.hkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17545373

Citation

Chiu, Susan S., et al. "Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children." Pediatrics, vol. 119, no. 6, 2007, pp. 1076-82.
Chiu SS, Peiris JS, Chan KH, et al. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics. 2007;119(6):1076-82.
Chiu, S. S., Peiris, J. S., Chan, K. H., Wong, W. H., & Lau, Y. L. (2007). Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics, 119(6), 1076-82.
Chiu SS, et al. Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children. Pediatrics. 2007;119(6):1076-82. PubMed PMID: 17545373.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. AU - Chiu,Susan S, AU - Peiris,J S Malik, AU - Chan,Kwok H, AU - Wong,Wilfred Hing Sang, AU - Lau,Yu Lung, PY - 2007/6/5/pubmed PY - 2007/7/10/medline PY - 2007/6/5/entrez SP - 1076 EP - 82 JF - Pediatrics JO - Pediatrics VL - 119 IS - 6 N2 - OBJECTIVES: We conducted this study to test the hypothesis that intradermal influenza vaccination at one fifth of a standard dose elicits comparable immunogenicity to full-dose intramuscular vaccination in children. PATIENTS AND METHODS: We conducted a randomized, open-label study in 112 healthy children aged 3 to <18 years to compare the immunogenicity and safety of intradermal vaccination at one fifth of a dose with standard intramuscular vaccination. Analyses of hemagglutination inhibition antibody titers to each antigen in each group included geometric mean titers before and 21 days after vaccination, fold increase in geometric mean titers after vaccination, seroprotection rate, and seroconversion rate. RESULTS: The mean age of the subjects was 10.11 +/- 4.04 years in the intradermal vaccination group and 10.57 +/- 3.91 years in the intramuscular group. Intradermal vaccination was safe. Induration and mild erythema at the injection site were reported at 25% and 57%, respectively, in the intradermal group. Fold increase of geometric mean titers against influenza A/Caledonia was robust in both groups (11.1-fold and 12.9-fold increase in the intramuscular and intradermal groups, respectively), whereas that for B/Shandong was more modest (4.3-4.4). Both approaches elicited very high geometric mean titers against influenza A/Panama: 1360.5 and 893.9 for the intramuscular and intradermal groups, respectively, but because the prevaccination antibody titers were high, the fold increase of geometric mean titers was only 4.5 and 2.6, respectively. CONCLUSION: The immunogenicity of one fifth of a dose of influenza vaccine delivered by the intradermal route is comparable to the standard-dose intramuscular vaccination in children as young as 3 years of age. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/17545373/Immunogenicity_and_safety_of_intradermal_influenza_immunization_at_a_reduced_dose_in_healthy_children_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&amp;pmid=17545373 DB - PRIME DP - Unbound Medicine ER -